Rising Prevalence Of Alzheimer’s Disease To Drive Market Growth Is Supporting Development Across The Alzheimer’s Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Alzheimer’s Drugs Market Between 2026 And 2030?

The alzheimer’s drugs market size has experienced significant growth in recent years. It is forecast to grow from $10.09 billion in 2025 to $10.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.9%. The market’s past expansion can be attributed to factors like an increasing elderly population, the rising prevalence of Alzheimer’s disease, greater awareness of dementia care, limited treatment options in earlier periods, and advancements in neuroscience research.

The market for Alzheimer’s drugs is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $15.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.8%. This anticipated growth during the forecast period is attributable to several factors, including progress in precision medicine, the incorporation of AI into drug development, the enlargement of healthcare infrastructure, governmental assistance and financing for dementia research, and the proliferation of digital health monitoring solutions. Key trends identified for this forecast period encompass the development of personalized Alzheimer’s therapies, breakthroughs in neuroprotective drugs, solutions for early diagnosis and screening, the emergence of combination and multi-target drugs, and advancements in patient adherence and monitoring solutions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

What Market Drivers Are Helping Shape The Alzheimer’s Drugs Market Expansion?

The expanding occurrence of Alzheimer’s disease is projected to fuel the growth of the Alzheimer’s drugs market in the future. This neurological condition progressively worsens over time, resulting in both brain shrinkage and the death of cells. Medications for Alzheimer’s disease are utilized to manage memory loss, difficulties with thinking and reasoning, and challenges in performing daily activities. These drugs can enhance the quality of life and assist in maintaining independence. For instance, in May 2024, a report by the Alzheimer’s Association, a US-based nonprofit organization dedicated to Alzheimer’s care, support, and research, showed that the count of Americans aged 65 and older diagnosed with Alzheimer’s dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024. Therefore, the rising prevalence of Alzheimer’s disease is driving the growth of the Alzheimer’s drugs market.

What Segment Types Are Included In The Alzheimer’s Drugs Market Analysis?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

Which Trends Are Influencing The Direction Of The Alzheimer’s Drugs Market?

Leading companies in the Alzheimer’s drugs market are developing innovative products, such as amyloid plaque-targeting therapy, to enhance treatment options and improve patient outcomes. This treatment approach for Alzheimer’s disease focuses on reducing or preventing the buildup of amyloid-beta plaques in the brain. For instance, in June 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), a US-based federal agency tasked with protecting public health. Kisunla (donanemab-azbt) represents the first and only amyloid plaque-targeting therapy for early symptomatic Alzheimer’s disease. It functions by helping the body eliminate excess amyloid plaques from the brain, which are linked to cognitive decline in Alzheimer’s patients. Kisunla is given as an intravenous infusion every four weeks. The initial dosing regimen involves 700 mg for the first three doses, followed by 1400 mg thereafter. Kisunla is specifically indicated for adults with mild cognitive impairment (MCI) and mild dementia stages of Alzheimer’s disease, provided they have confirmed amyloid pathology.

Which Companies Form The Competitive Landscape Of The Alzheimer’s Drugs Market?

Major companies operating in the alzheimer’s drugs market are AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC, Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc.

Access The Complete Alzheimer’s Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Which Region Accounts For The Highest Share Of The Alzheimer’s Drugs Market?

North Americawas the largest region in the Alzheimer’s drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the alzheimer’s drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Alzheimer’s Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

Browse Through More Reports Similar to the Global Alzheimer’s Drugs Market 2026, By The Business Research Company

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795